157 related articles for article (PubMed ID: 32642716)
1. MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.
Su YT; Butler M; Zhang M; Zhang W; Song H; Hwang L; Tran AD; Bash RE; Schorzman AN; Pang Y; Yu G; Zamboni WC; Wang X; Frye SV; Miller CR; Maric D; Terabe M; Gilbert MR; Earp Iii HS; Wu J
Neurooncol Adv; 2020; 2(1):vdaa065. PubMed ID: 32642716
[TBL] [Abstract][Full Text] [Related]
2. MerTK as a therapeutic target in glioblastoma.
Wu J; Frady LN; Bash RE; Cohen SM; Schorzman AN; Su YT; Irvin DM; Zamboni WC; Wang X; Frye SV; Ewend MG; Sulman EP; Gilbert MR; Earp HS; Miller CR
Neuro Oncol; 2018 Jan; 20(1):92-102. PubMed ID: 28605477
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
4. Extract of Astragali Radix and Solanum nigrum Linne regulates microglia and macrophage polarization and inhibits the growth and infiltration of C6 glioblastoma.
Shen M; Liu S; Wei Q; Zhang X; Wen S; Qiu R; Li Y; Fan H
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117067. PubMed ID: 37619857
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
Summers RJ; Jain J; Vasileiadi E; Smith B; Chimenti ML; Yeung TY; Kelvin J; Wang X; Frye SV; Earp HS; Tyner JW; Dreaden EC; DeRyckere D; Graham DK
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551626
[TBL] [Abstract][Full Text] [Related]
6. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
7. Dicer deficiency impairs proliferation but potentiates anti-tumoral effect of macrophages in glioblastoma.
Liu YQ; Luo M; Shi Y; Guo Y; Zhang H; Yang KD; Li TR; Yang LQ; Liu TT; Huang B; Liu Q; He ZC; Zhang XN; Wang WY; Wang S; Zeng H; Niu Q; Zhang X; Cui YH; Zhang ZR; Bian XW; Ping YF
Oncogene; 2022 Jul; 41(30):3791-3803. PubMed ID: 35764885
[TBL] [Abstract][Full Text] [Related]
8. FTY720 Exerts Anti-Glioma Effects by Regulating the Glioma Microenvironment Through Increased CXCR4 Internalization by Glioma-Associated Microglia.
Guo XD; Ji J; Xue TF; Sun YQ; Guo RB; Cheng H; Sun XL
Front Immunol; 2020; 11():178. PubMed ID: 32194542
[No Abstract] [Full Text] [Related]
9. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
10. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.
Zeiner PS; Preusse C; Golebiewska A; Zinke J; Iriondo A; Muller A; Kaoma T; Filipski K; Müller-Eschner M; Bernatz S; Blank AE; Baumgarten P; Ilina E; Grote A; Hansmann ML; Verhoff MA; Franz K; Feuerhake F; Steinbach JP; Wischhusen J; Stenzel W; Niclou SP; Harter PN; Mittelbronn M
Brain Pathol; 2019 Jul; 29(4):513-529. PubMed ID: 30506802
[TBL] [Abstract][Full Text] [Related]
11. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
12. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
13. Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy.
Lin C; Wang N; Xu C
Front Immunol; 2023; 14():1123853. PubMed ID: 36969167
[TBL] [Abstract][Full Text] [Related]
14. Exploiting Microglial Functions for the Treatment of Glioblastoma.
Dello Russo C; Lisi L; Tentori L; Navarra P; Graziani G; Combs CK
Curr Cancer Drug Targets; 2017; 17(3):267-281. PubMed ID: 27528361
[TBL] [Abstract][Full Text] [Related]
15. CXCL16/CXCR6 Axis Drives Microglia/Macrophages Phenotype in Physiological Conditions and Plays a Crucial Role in Glioma.
Lepore F; D'Alessandro G; Antonangeli F; Santoro A; Esposito V; Limatola C; Trettel F
Front Immunol; 2018; 9():2750. PubMed ID: 30542347
[TBL] [Abstract][Full Text] [Related]
16. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
[TBL] [Abstract][Full Text] [Related]
17. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
18. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
19. Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.
Szulzewsky F; Schwendinger N; Güneykaya D; Cimino PJ; Hambardzumyan D; Synowitz M; Holland EC; Kettenmann H
Neuro Oncol; 2018 Feb; 20(3):355-366. PubMed ID: 29016864
[TBL] [Abstract][Full Text] [Related]
20. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
Minson KA; Smith CC; DeRyckere D; Libbrecht C; Lee-Sherick AB; Huey MG; Lasater EA; Kirkpatrick GD; Stashko MA; Zhang W; Jordan CT; Kireev D; Wang X; Frye SV; Earp HS; Shah NP; Graham DK
JCI Insight; 2016 Mar; 1(3):e85630. PubMed ID: 27158668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
